Key Highlights

  • PRFX was up 13.64 percent to USD 0.8297 in pre-market trading on November 2, 2026.
  • No company announcement dated between October 24 and November 2, 2026 was identified.
  • A Shareholder letter dated October 23, 2026 cited preliminary cash of about USD 11.0 million at September 30, 2026.
  • Operating loss was about USD 3.7 million for the nine months ended September 30, 2026, preliminary and unaudited.
  • A U.S. Phase 2 trial of OcuRing-K is expected to begin enrolling before year-end 2026.

What moved the shares before the open

PRF Technologies (NASDAQ:PRFX) was up 13.64 percent to USD 0.8297 in pre-market trading on November 2, 2026. No company press release or filing dated after the October 23, 2026 shareholder letter was identified, so the trigger is unconfirmed.

The stock sits under USD 1 with a small public float, and shares in that position can swing sharply on modest volume. Recent themes around AI Data Center power may also be drawing interest to the company's energy software unit.

The latest company updates

In a shareholder letter from interim chief executive Efraim Cohen-Arazi dated October 23, 2026, the company said cash including short-term deposits was about USD 11.0 million at September 30, 2026, against total liabilities of about USD 2.5 million. Both figures are preliminary and unaudited.

The letter said Subsidiary LayerBio expects to start enrolling patients in a U.S. multi-center Phase 2 trial of OcuRing-K before year-end 2026, subject to completing start-up activities. The trial will assess pain, inflammation and safety after cataract surgery.

Business background

PRF Technologies is based in Tel Aviv, Israel, and focuses on reformulating established therapeutics using an extended-release drug delivery system aimed at prolonged post-surgical pain relief and less reliance on opioids. It also develops AI-driven energy software through its DeepSolar and GridFeed platforms.

In a company press release dated September 16, 2026, the company said GridFeed is exploring AI and hyperscale data center power optimization. On September 9, 2026 it announced plans to place GridFeed and DeepSolar in a standalone, wholly owned subsidiary.

Funding and risks

The company raised about USD 10.5 million in gross proceeds through an Equity line Facility in the nine months ended September 30, 2026. Equity line funding typically involves issuing new shares, which can dilute existing holders. The company lists its ability to maintain its Nasdaq Capital Market listing among its risk factors.

Penny stocks like PRFX can be highly volatile and illiquid, and pre-market prices may differ from regular trading. The company also noted limited experience in the data center market and a history of losses.

What to watch next

Key items include the first patient enrollment in the OcuRing-K Phase 2 trial, any update on the GridFeed subsidiary and data center partners, and the final third quarter figures once closing procedures are complete.